Givaudan SA (0QPS)
London Stock Exchange · UK · prices in GBP · close of 27 Oct 2026
Key indicators
| Last close | GBP 3,921.00 |
|---|---|
| 52-week range | 2,542.00 – 3,984.50 |
| Return, 1 month / 3 months | +14.2% / +23.4% |
| Return, 1 year / 3 years | +12.9% / +30.5% |
| Trend | Uptrend |
| RSI (14) | 73 |
| Volatility (1 year) | 27.5% |
| Worst drawdown (1 year) | -25.5% |
| Average daily value traded | 17.93M GBP |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Givaudan SA is a Swiss company that creates flavours and fragrances. It develops flavour ingredients and compounds used in food, beverages and other consumer products, and fragrance ingredients and compounds used in perfumes, personal care items and household goods. Its customers are manufacturers in the food, drink, cosmetics and home care industries, and it is based in Vernier, near Geneva, with operations in many countries around the world.
The shares are listed on the London Stock Exchange in UK under the code 0QPS, and the price on this page is in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Givaudan SA (0QPS) trades on the London Stock Exchange in UK. It last closed at GBP 3,921.00 on 27 October 2026.
Its price-based Market X-Ray is 76 out of 100 (a strong price profile), ranking 217 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 12.9% and over the last three months it rose 23.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 87 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 24.8% | ||
| From 52-week high | -1.6% | ||
| Momentum | 75 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 23.4% | ||
| 6-month return | 38.2% | ||
| 12-month return, skipping the last month | -1.2% | ||
| Stability (higher is calmer) | 64 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 27.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.5% | ||
| Liquidity | 78 · Strong | Trades actively. | |
| Average daily value traded | 17.93M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −0.8% |
|---|---|
| 1 month | +14.2% |
| 3 months | +23.4% |
| 6 months | +38.2% |
| 1 year | +12.9% |
| 3 years | +30.5% |
| 5 years | −10.2% |
Signals
| 50-day / 200-day average | 3,448.44 / 3,141.38 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 71.57 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 23 Mar 2026 | GBX 0.7200 |
| 23 Mar 2025 | GBX 0.7000 |
| 25 Mar 2024 | GBX 0.6800 |
| 27 Mar 2023 | GBX 0.6700 |
| 28 Mar 2022 | GBX 0.6600 |
| 29 Mar 2021 | GBX 0.6400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.